9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given the demonstrated benefits of SGLT2 inhibitors, the updated American Diabetes Association guidelines10 and the American College of Cardiology expert consensus statement11 now recommend their use for diabetic patients who have or are at high risk for cardiovascular disease, CKD, or heart failure regardless of current glycemic control.”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [10]
In the citing paper
“All recommend SGLT2 inhibition for patients with T2DM and eGFR as low as 30 mL/min/1.73 m2, particularly if severely increased albuminuria is present.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“Major national and international organizations are rapidly updating recommendations and guidelines (Table 4) (85–88).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“In the US, the 2020 national median drug acquisition cost of GLP-1RAs ranges from $634 per month to $835 per month,27·41 although the out-of-pocket cost borne by patients varies considerably by insurance formulary and coverage.”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [27]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“may reduce risk of cardiovascular events and death (35).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682 · cited 1×
“first-line therapy hasbeneficial effects on A1C, weight, and cardiovascular mortality (36); there is little systematic data”
BackgroundThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“with type 1 diabetes (15,16), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (17).”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Research works printed but not linked: 1
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
Cited by
Items 501–600 of 958
de Carvalho, F. S., Marques, F. D. B., Lopes, A. E., Ferreira, J. L., & Príncipe, R. M. (2023) · Cureus · doi:10.7759/cureus.33509 · Cited by 11
Reinforcement Learning for Multiple Daily Injection (MDI) Therapy in Type 1 Diabetes (T1D)
Jaloli, M., & Cescon, M. (2023) · BioMedInformatics · doi:10.3390/biomedinformatics3020028 · Cited by 8
Shapiro, S. B., Yin, H., Yu, O. H. Y., & Azoulay, L. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16039 · Cited by 8
“5 We chose DPP-4 inhibitors as the active comparator group since they are common second-to-third line drugs for the treatment of type 2 diabetes 6,7 and have not been shown to be associated with lung cancer.”
Second revolution in cardiovascular prevention
Chiang, C., Wang, K.-L., Cheng, H., Sung, S., & Chao, T. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000276 · Cited by 8
Julian, G. S., Campos, D., Honoré, J. B., Tobaruella, F. S., Yoon, J. H., & Hallén, N. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1764966 · Cited by 30
Morales, J., Kuritzky, L., Lavernia, F., & Santiago, M. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1857603 · Cited by 8
Desouza, C. V., Kirk, A. R., Mangla, K. K., Wolden, M. L., & Lingvay, I. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001830 · Cited by 8
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
Blonde, L., Rosenstock, J., Frías, J. P., Birkenfeld, A. L., Niemoeller, E., Souhami, E., Ji, C. F., Prato, S. D., & Aroda, V. R. (2021) · Diabetes Care · doi:10.2337/dc20-2023 · Cited by 8
Soroosh, G., Dzaye, O. D. A., Reiter–Brennan, C., & Blaha, M. J. (2021) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000243 · Cited by 9
Plum‐Mörschel, L., Singh, G., Murugesan, S. M. N., Marwah, A., Panda, J., Loganathan, S., & Athalye, S. N. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14635 · Cited by 8
Wachtendorf, L. J., Azimaraghi, O., Rangasamy, V., Sane, M., Subramaniam, B., Vázquez, R., Wongtangman, K., Houle, T. T., Bellin, E. Y., Akeju, O., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005544 · Cited by 8
Canagliflozin: metabolic, Cardiovascular and Renal Protection
Barrios, V., & Escobar, C. (2021) · Future Cardiology · doi:10.2217/fca-2020-0192 · Cited by 8
Combined Albuminuria and Estimated GFR Laboratory Reporting Affects Primary Care Management of CKD
Vassalotti, J. A., & Thavarajah, S. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.04.005 · Cited by 10
Wu, J., Perez, A., & Sullivan, P. W. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.10.1029 · Cited by 7
Yao, Y., Liu, N., Chen, S., Sun, M., & Guo, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-03241-8 · Cited by 7
“Our results, confirming significant CV risk reduction—especially in high-risk CKD patients—support current guidelines from the ADA and EASD that recommend prioritizing GLP-1RAs with proven benefit in T2D patients with elevated CV risk [59, 60].”
Aditama, L., Athiyah, U., Utami, W., & Qomaruddin, M. B. (2021) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/6xhncimtpz · Cited by 7
Linagliptin-Induced Arthralgia
Nigro, S. C., & Goldman, J. D. (2021) · Clinical Diabetes · doi:10.2337/cd20-0110 · Cited by 7
Vázquez-Agra, N., Fernández-Crespo, S., Marques-Afonso, A.-T., Cruces‐Sande, A., Gouveia, S., Olmos, M. Á. M., & Ameijeiras, Á. H. (2023) · Medicina Clínica · doi:10.1016/j.medcli.2022.09.025 · Cited by 7
Nagasawa, S., Yamaguchi, R., Chiba, F., Torimitsu, S., & Iwase, H. (2023) · Journal of Forensic Sciences · doi:10.1111/1556-4029.15219 · Cited by 7
Yu, R., Liu, X., Li, R., & Xiao, X. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13477 · Cited by 7
Kutoh, E., Kuto, A. N., Wada, A., Hayashi, J., & Kurihara, R. (2020) · Drug Research · doi:10.1055/a-1304-3430 · Cited by 7
The Evolution of Insulin Administration in Type 1 Diabetes
Pinnaro, C. T., & Tansey, M. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115021 · Cited by 9
“Basal-bolus therapy is standard-of-care in T1D and can be achieved using regular human insulin or rapid-acting insulin analogs (lispro, aspart, glulisine) for prandial coverage [37,38].”
BackgroundBeamish, C. A., Gaber, A. O., Fraga, D. W., Hamilton, D. J., & Sabek, O. M. (2022) · Transplantation Direct · doi:10.1097/txd.0000000000001367 · Cited by 7
Methnani, J., Hajbelgacem, M., Ach, T., Chaieb, F., Sellami, S., Bouslama, A., Zaouali, M., Omezzine, A., & Bouhlel, E. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231156318 · Cited by 8
“10 The drug has also gained momentum outside the spectrum of T2D and has now entered the realms of cancer, aging and CVDs.”
BackgroundKosachunhanun, N., Wongsa, D., & Permsuwan, U. (2023) · Healthcare · doi:10.3390/healthcare11070949 · Cited by 7
Shapiro, S. B., Yin, H., Yu, O. H. Y., & Azoulay, L. (2024) · Drug Safety · doi:10.1007/s40264-024-01434-4 · Cited by 8
“We chose SGLT-2 inhibitors as the comparator since they are common second-to-third line drugs for the treatment of type 2 diabetes [2, 26, 27] and were not found to be associated with gallbladder or bile duct disease [17].”
An, J., Sim, J. J., Zhou, M. M., Zhou, H., Choi, S. K., Brettler, J. W., Ong‐Su, A. L., & Reynolds, K. (2024) · Journal of Clinical Hypertension · doi:10.1111/jch.14915 · Cited by 7
Chen, C.-F., Chen, Y., Chen, T., Chen, F.-Y., Yang, Y.-P., Wang, M., Huo, T., Chang, Y.-L., Tan, A. C., & Lin, C. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000354 · Cited by 8
Patel, K. V., Sarraju, A., Neeland, I. J., & McGuire, D. K. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01355-5 · Cited by 7
Federici, M. O., Gentilella, R., Corcos, A., Torre, E., & Genovese, S. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3434 · Cited by 8
Rigalleau, V., Larroumet, A., Ducos, C., Rigo, M., Barbet‐Massin, M., Majchrzak, C., Mohammedi, K., Baillet‐Blanco, L., Monlun, M., Arab, L. R., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108234 · Cited by 7
Jinglong, L., Me, R. C., & Ahmad, F. A. (2024) · Springer series in design and innovation · doi:10.1007/978-3-031-60863-6_5 · Cited by 7
Katsiki, N., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154333 · Cited by 7
Costa, G. C., Montagnoli, T. L., da Silva, J. S., Alencar, A. K. N., Gamba, L. E. R., Alves, B. E. O., Silva, M. M., Trachez, M. M., Nascimento, J. H. M., Pimentel‐Coelho, P. M., et al. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s258459 · Cited by 7
Boye, K. S., Sapin, H., García‐Pérez, L., Rosilio, M., Federici, M. O., Heitmann, E., Jung, H., Aigner, U., Guerci, B., Giorgino, F., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00908-9 · Cited by 7
Injection Technique: Development of a Novel Questionnaire and User Guide
Barnard-Kelly, K. D., Mahoney, E., Baccari, L., Oliveria, T., Glezer, S., Berard, L., & Morel, D. R. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0054 · Cited by 7
Velojić-Golubović, M., Ćirić, V. M., Dimitrijevic, M., Ković, T., Mitic, M., Olujic, B., Pevac, N., Radenković, S., Radojković, D., Vukadinovic, S., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01074-2 · Cited by 7
Settles, J. A., Kan, H. J., Child, C. J., Gorritz, M., Multani, J. K., McGuiness, C. B., Wade, R. L., & Frier, B. M. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14690 · Cited by 8
Masuda, H., Ishiyama, D., Yamada, M., Iwashima, F., Kimura, Y., Otobe, Y., Tani, N., Suzuki, M., & Nakajima, H. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s307070 · Cited by 6
Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
Weiss, T., Iglay, K., Gulati, T., Rajpathak, S., Yang, L., & Blonde, L. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002127 · Cited by 6
Bramlage, P., Vijayan, A., Varghese, T. P., Sadanandan, D. M., Lanzinger, S., & Rodriguez, C. F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70010 · Cited by 7
Metformin alleviates inflammatory responses in acute allergic asthma by inhibiting ILC2s function
Liu, Z., Jing, X., Lu, Y., Jiang, Z., Lu, Y., Peng, J., Xu, X., Liu, H., Ren, L., & Tang, H. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114897 · Cited by 6
Pamulapati, L. G., Rochester-Eyeguokan, C. D., & Pincus, K. J. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa243 · Cited by 6
Strojek, K., Pandey, A. S., Dell, V., Sisson, M., Wang, S., Huyck, S. B., Liu, J., & Gantz, I. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01018-w · Cited by 7
Shin, Y., Choi, H., & Lim, S. K. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108843 · Cited by 6
Nelson, D. R., Heaton, P. C., Hincapie, A. L., Ghodke, S. D., & Chen, J. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01098-8 · Cited by 7
SGLT2-Inhibitoren: Was gibt es Neues?
Dumann, E., & Menne, J. (2021) · Der Nephrologe · doi:10.1007/s11560-021-00511-4 · Cited by 6
Choosongsang, P., & Soonthornpun, S. (2021) · Diabetic Medicine · doi:10.1111/dme.14659 · Cited by 6
Identifying Drug-Therapy Problems among Syrian Refugees in Zaatari Refugee Camp
Hammad, A. M., Al-Qerem, W. A., Alasmari, F. F., Ling, J., Qarqaz, R., & Alaqabani, H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19127199 · Cited by 7
Panchal, R., Nguyen, D. T., Ghule, P., Li, N., Giannouchos, T. V., Pan, R. J., BISKUPIAK, J. E., Britton, L., Nohavec, R., Slager, S. L., et al. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.2.139 · Cited by 7
Insulin Therapy in Small Animals, Part 1: General Principles
Fleeman, L. M., & Gilor, C. (2023) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2023.02.002 · Cited by 6
Trueman, C., Shin, E. H., Donovan, A., McAdam‐Marx, C., & Coan, C. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.12.1275 · Cited by 7
Nugraha, A. S., Kintoko, K., Putri, C. P. Z. S., Az-Zahra, F., Firli, L. N., Rani, D. M., Purnomo, Y. D., Nguyen, P. T. V., Puspitasari, R. M., Hartati, T., et al. (2025) · Phytochemistry Reviews · doi:10.1007/s11101-025-10173-y · Cited by 6
“Diabetes is a chronic disease characterized by either the pancreas’ inability to produce sufficient insulin or the body’s inability to effectively utilize the insulin it produces.”
InfluentialRados, D. R. V., Viecceli, C., Pinto, L. C. F., Gerchman, F., Leitão, C. B., & Gross, J. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-69738-w · Cited by 7
Kapitza, C., Nosek, L., Schmider, W., Teichert, L., Mukherjee, B., & NOWOTNY, I. K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14260 · Cited by 6
Meade, L. T., & Battise, D. M. (2021) · Clinical Diabetes · doi:10.2337/cd20-0094 · Cited by 6
Yang, C.-T., Li, K.-Y., Yang, C., Ou, H., & Kuo, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-83253-6 · Cited by 6
Evolving Concepts of Type 2 Diabetes Management
Abushamat, L. A., & Reusch, J. E. B. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.06.003 · Cited by 7
Chen, X., Jiang, H., Li, H., Kuang, H., Chen, L., Ma, J., Zhang, Q., Pan, T., Yang, W., & SUCCESS study investigators (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14873 · Cited by 6
Non-cardiac comorbidities in heart failure: an update on diagnostic and management strategies
Kodur, N., & Tang, W. H. W. (2024) · Minerva Medica · doi:10.23736/s0026-4806.24.09070-0 · Cited by 6
Verma, S., Klug, E., Mareev, V. Y., Kobalava, Z. D., Connelly, K. A., Arıcı, M., Berwanger, O. B., Santoso, A., Mehta, R., Meglis, G., et al. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000774 · Cited by 6
Practical Considerations and Opportunities for SGLT2 Inhibitor Prescription in Heart Failure
Faulkenberg, K. D., Williams, J. B., Isaacs, D. M., & West, L. M. (2020) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-020-00825-x · Cited by 6
Intensive Insulin Therapy (Basal-Bolus)
Chico, A. I., & Corcoy, R. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001152 · Cited by 6
Han, E., Lee, M., Lee, Y., Kim, H. S., Lee, B., Soo, B., & Kang, E. S. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s267994 · Cited by 6
An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes
Chatzopoulos, G., & Τζιόμαλος, Κ. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1793961 · Cited by 7
Bae, J. H., Ahn, C. H., Yang, Y., Moon, S. J., Kwak, S. H., Jung, H. S., Park, K. S., & Cho, Y. M. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0274 · Cited by 7
“Insulin therapy should also be considered when patients have evidence of catabolic features such as weight loss and ketosis or have severe and symptomatic hyperglycemia [17].”
Das, B., Sheikh, A., Ahmed, B., & Islam, N. (2021) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.37.5.3901 · Cited by 6
Cost–effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes
Zupa, M. F., Codario, R. A., & Smith, K. J. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2021-0016 · Cited by 6
Oral semaglutide: the innovation in type 2 diabetes management
Shestakova, M. V., Шамхалова, М. Ш., Galstyan, G. R., Ruyatkina, L. A., & Суплотова, Л. А. (2021) · Diabetes Mellitus · doi:10.14341/dm12790 · Cited by 6
Gu, S., Gu, J., Wang, X., Wang, X., Li, L., Gu, H., & Xu, B. (2024) · Health Economics Review · doi:10.1186/s13561-024-00499-2 · Cited by 5
Khezri, M. R., Pashaei, M. R., Ghasemnejad‐Berenji, M., & Ghasemnejad‐Berenji, H. (2024) · Reproductive Toxicology · doi:10.1016/j.reprotox.2024.108672 · Cited by 5
Ramadan fasting and glycemic control in patients with type 2 diabetes: A real-world data analysis
Swan- Abu Salih, A., Chodick, G., Klein, P., & Eilat-Adar, S. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2024.12.010 · Cited by 5
Sharma, A., Suvedi, D., Kumar, A., Khanal, S., Verma, R., Kumar, D., Kumar, D., Tapwal, A., Kumar, V., & Peter, L. (2025) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-025-04687-y · Cited by 6
“As such, Ganoderma -based bioactives may offer complementary alternatives (Wakeman and Archer 2020; Association 2020).”
Warden, B. A., Steiner, J., Camacho, A., Nguyen, K. A., Purnell, J. Q., Duell, P. B., Craigan, C., Osborn, D., & Fazio, S. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100183 · Cited by 6
Targeting metabolism in the management of PCOS: Metformin and beyond
Oğuz, S. H., Şendur, S. N., Ünlütürk, U., & Yıldız, B. O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823045-9.00006-7 · Cited by 6
Eyüboğlu, M., & Çelik, A. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13734 · Cited by 5
Nasser, S. A., Arora, N., & Ferdinand, K. C. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2312411 · Cited by 5
Deerochanawong, C., Krittayaphong, R., Romano, J. G. U., Rhee, N. A., & Permsuwan, U. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01371-y · Cited by 5
Unnikrishnan, P. S., Suthindhiran, K., & Jayasri, M. A. (2023) · Aquaculture International · doi:10.1007/s10499-023-01311-4 · Cited by 6
“However, insulin therapy and insulin secretagogues were reported to cause a lethal reduction in blood glucose levels resulting in hypoglycemia (The American Diabetes Association 2020).”
BackgroundAyres, A. B. S., Carneiro, C. R. G., Gestic, M. A., Utrini, M. P., Chaim, F. D. M., Callejas-Neto, F., Chaim, É. A., & Cazzo, E. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06986-5 · Cited by 5
“This is so relevant that there is a formal recommendation for diabetes screening in patients with NAFLD and vice versa [44].”
Mahmoud, F., Mueller, T., Mullen, A. B., Sainsbury, C. A. R., Rushworth, G. F., & Kurdi, A. B. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15584 · Cited by 5
Jinglong, L., Me, R. C., Ahmad, F. A., & Zhu, Q. (2024) · International Journal of Religion · doi:10.61707/ah32h289 · Cited by 5
“…Dietary guidance is especially important among these components due to its ability to regulate blood sugar levels and lower the risk of diabetes-related complications, ultimately supporting better health outcomes in elderly individuals with diabetes (American Diabetes Association, 2020).”
BackgroundCardiovascular Risks With SGLT2 Inhibitors in Clinical Practice Among Patients With Type 2 Diabetes
Su, H., Yang, C., Lee, Y., Su, P., Liu, Y.-C., & Ou, H. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.41765 · Cited by 5
Gul, N., Rehman, I. U., Shah, Y., Ali, A. M., Ali, Z., Shehzad, O., Goh, K. W., Ming, L. C., & Suleiman, A. K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311435 · Cited by 6
Complicaciones macrovasculares de la diabetes
Costo-Muriel, C., Carmona, J. M., & Perez-Belmonte, L. M. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.011 · Cited by 9
Insulinización práctica en la diabetes mellitus tipo 2
Naranjo, E. G. B., Campos, G. F. C., & Fallas, Y. M. G. (2021) · Revista Medica Sinergia · doi:10.31434/rms.v6i1.628 · Cited by 10
Ritzel, R. A., Ghosh, S. K., Emral, R., Malek, R., Zeng, L., Mabunay, M. A., Landgraf, W., Guyot, P., Serafini, P. R., Pushkarna, D., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15121 · Cited by 6
Chonko, K., Russo‐Alvarez, G., Isaacs, D. M., Wang, L., & Soric, A. (2023) · INNOVATIONS in pharmacy · doi:10.24926/iip.v14i2.5456 · Cited by 5
Boškoski, I., Orlandini, B., Gallo, C., Bove, V., Pontecorvi, V., Perri, V., & Costamagna, G. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1757429 · Cited by 5
Arbel, R., Aboalhasan, E., Hammerman, A., & Azuri, J. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00929-z · Cited by 5
Chewcharat, A., Takkavatakarn, K., Isaranuwatchai, S., Katavetin, P., Praditpornsilpa, K., Eiam‐Ong, S., & Susantitaphong, P. (2020) · International Urology and Nephrology · doi:10.1007/s11255-020-02520-z · Cited by 6
John, M., Gopinath, D., & Oommen, T. (2020) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000509045 · Cited by 7
Rozado, J., Iglesias, D. G., Soroa, M., Junco-Vicente, A., Barja, N., Adeba, A., Vigil-Escalera, M., Alvarez, R. F., Saura, F. T., Capín, E., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082600 · Cited by 5
Zhang, H., Barner, J. C., Moczygemba, L. R., & Rascati, K. L. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.11.1434 · Cited by 6
Vlacho, B., Mundet, X., Mata‐Cases, M., Vallès-Callol, J. A., Real, J., Farré, M., Cos, X., Khunti, K., Mauricio, D., & Franch‐Nadal, J. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108616 · Cited by 6
Yoon, J. H., Hong, A. R., Choi, W., Park, J. Y., Kim, H. K., & Kang, H. (2021) · Chonnam Medical Journal · doi:10.4068/cmj.2021.57.3.211 · Cited by 5
Flory, J., Li, J., Dawwas, G. K., & Leonard, C. E. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.245 · Cited by 5
Comparison between insulin delivery methods: subcutaneous, inhaled, oral, and buccal
Juárez, B. A., la Parra, P. F.-D., Rayo-Mercado, K. T. E., & Ponce-López, T. (2021) · Proceedings of Scientific Research Universidad Anáhuac Multidisciplinary Journal of Healthcare · doi:10.36105/psrua.2021v1n1.08 · Cited by 5
Cardioprotective Effects of Pioglitazone in Type 2 Diabetes
Tripathy, D., Solis‐Herrera, C., & Ryder, R. E. J. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0078 · Cited by 7
“Along with comprehensive lifestyle modi fi cation, metformin is recommended as the fi rst-line therapy for all patients with type 2 diabetes, and other medications may be added subsequently (55).”
BackgroundCoke, L. A., DEEDWANIA, P. C., Hinnen, D., Magwire, M., & Miller, N. H. (2022) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000661 · Cited by 6
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-16
- Volume
- 43
- Issue
- Supplement_1
- Pages
- S98-S110
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4246340431
- Cited by
- 914
- References
- 84
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 69 · 2023: 100 · 2022: 151 · 2021: 270 · 2020: 268
- FWCI
- 140.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Glycemic Control, Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Hypoglycemic Agents, Reference Standards, Societies, Medical, United States, History, 21st Century, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.